Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update [Yahoo! Finance]
Vor Biopharma Inc. (VOR)
Company Research
Source: Yahoo! Finance
In This Article VOR Vor Biopharma On-track for trem-cel + Mylotarg™ and VCAR33 ALLO clinical updates in the second half of 2024 CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended June 30, 2024, and provided a corporate update. “We are pleased with the progress we have made with enrollment of both the trem-cel + Mylotarg and VCAR33 ALLO clinical trials during the quarter,” said Dr. Robert Ang, Vor Bio's President and Chief Executive Officer. “Every year, thousands of patients with AML and MDS relapse post-transplant with no safe and effective treatment options. Our approach of shielded transplants may provide the first opportunity to deliver curative treatments post-transplant. We look forward to our next clinical update in the second half of this year.” Corporate Updates Trem-cel trial continues to enroll rapidly and patients ar
Show less
Read more
Impact Snapshot
Event Time:
VOR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VOR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VOR alerts
High impacting Vor Biopharma Inc. news events
Weekly update
A roundup of the hottest topics
VOR
News
- Vor Bio Announces $150 Million Private PlacementGlobeNewswire
- Vor Biopharma (VOR): Valuation Check After Positive Telitacicept Phase 3 Data and Upbeat JPMorgan Coverage [Yahoo! Finance]Yahoo! Finance
- Vor Biopharma (NASDAQ:VOR) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $43.00 price target on the stock.MarketBeat
- Vor Biopharma (NASDAQ:VOR) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $9.00 price target on the stock.MarketBeat
- Vor Biopharma (NASDAQ:VOR) had its price target lowered by analysts at HC Wainwright from $55.00 to $32.00. They now have a "buy" rating on the stock.MarketBeat
VOR
Earnings
- 11/13/25 - Miss
VOR
Sec Filings
- 12/9/25 - Form 4
- 12/9/25 - Form 4
- 12/9/25 - Form 4
- VOR's page on the SEC website